Kindred Biosciences (KIN) Stock Price, Forecast & Analysis
NASDAQ:KIN
KIN Key Statistics, Chart & Performance
The current stock price of KIN is 9.25 null. In the past month the price increased by 1.43%. In the past year, price increased by 120.76%.
KIN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KIN. When comparing the yearly performance of all stocks, KIN is one of the better performing stocks in the market, outperforming 95.15% of all stocks.
KIN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KIN. While KIN seems to be doing ok healthwise, there are quite some concerns on its profitability.
KIN Financial Highlights
Over the last trailing twelve months KIN reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS decreased by -53.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -529.26% | ||
| ROA | -38.53% | ||
| ROE | N/A | ||
| Debt/Equity | 0.19 |
KIN Forecast & Estimates
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
For the next year, analysts expect an EPS growth of -51.22% and a revenue growth -49.68% for KIN
KIN Ownership
KIN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.14 | 414.026B | ||
| AMGN | AMGEN INC | 16.85 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.54 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.35 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.64 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.97 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.21 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.77 | 22.521B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KIN
Company Profile
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company is headquartered in Burlingame, California and currently employs 63 full-time employees. The company went IPO on 2013-12-12. The firm is focused on developing therapies for pets. The firm's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The firm is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The firm is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The firm's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The firm's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Company Info
Kindred Biosciences
1555 Bayshore Hwy Ste 200
Burlingame CALIFORNIA 94010 US
CEO: Richard Chin
Employees: 63
Phone: 16507017901.0
Kindred Biosciences / KIN FAQ
Can you describe the business of Kindred Biosciences?
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company is headquartered in Burlingame, California and currently employs 63 full-time employees. The company went IPO on 2013-12-12. The firm is focused on developing therapies for pets. The firm's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The firm is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The firm is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The firm's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The firm's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Can you provide the latest stock price for Kindred Biosciences?
The current stock price of KIN is 9.25 null. The price increased by 0.11% in the last trading session.
Does KIN stock pay dividends?
KIN does not pay a dividend.
How is the ChartMill rating for Kindred Biosciences?
KIN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting KIN stock to perform?
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
Can you provide the market cap for Kindred Biosciences?
Kindred Biosciences (KIN) has a market capitalization of 420.52M null. This makes KIN a Small Cap stock.
When does Kindred Biosciences (KIN) report earnings?
Kindred Biosciences (KIN) will report earnings on 2022-03-15, after the market close.